Latanoprost

Both Xalatan and Iyuzeh are labeled to lower elevated intraocular pressure in open-angle glaucoma or ocular hypertension. Pressure is a risk factor for optic-nerve and visual-field damage; the label indication does not establish treatment of every glaucoma subtype. Pediatric safety/effectiveness are not established in these U.S. labels.

Xalatan is a preserved multidose solution; Iyuzeh is preservative-free in single-dose containers. Both contain 0.005% latanoprost. The absence of preservative does not remove latanoprost’s pigmentation, inflammatory or macular-edema risks.

Xalatan and Iyuzeh: one drop in each affected eye once daily in the evening. If a dose is missed, skip it and continue the next scheduled dose normally. Do not exceed once daily or double a missed dose.

Remove contact lenses before either product and wait 15 minutes before reinserting. If using another topical eye medicine, separate administration by at least 5 minutes. Do not mix drops together in the container.

Wash hands and open a new single-dose container only when ready. One container can treat one or both eyes; use it immediately and discard all remaining solution after that administration. Avoid touching its tip to the eye or other surfaces; never save an opened container for another dose.

Avoid contact between the Xalatan dropper tip and the eye, fingers or surrounding structures. A contaminated bottle can cause serious eye infection. Ask the eye clinician about continued use after eye injury, infection, ocular reactions or surgery.

Known hypersensitivity to latanoprost or any product ingredient is contraindicated. Xalatan specifically includes benzalkonium chloride in its contraindication statement. Iyuzeh is preservative-free but contains other excipients; check the exact formulation before substituting.

The current Xalatan and Iyuzeh prescribing information reviewed here contains no FDA boxed warning. Their ocular warnings, handling instructions and allergy contraindications still apply.

Reported ocular effects include hyperemia, irritation, stinging/burning, foreign-body sensation, itching, blurred vision, tearing and punctate keratitis, with product-specific trial frequencies. Pigment/lash changes, uveitis, macular edema and corneal complications are important. Postmarketing reports include asthma worsening/dyspnea, headache/dizziness and rare severe skin reactions; spontaneous reports do not establish incidence or causality.

Combining two or more prostaglandins or prostaglandin analogs is not recommended. More-than-once-daily administration of these agents can weaken pressure reduction or cause paradoxical pressure increases. Other classes may be combined when prescribed, with at least 5 minutes between eye drops.

Xalatan can precipitate when mixed in vitro with thimerosal-containing eye drops; separate topical administrations by at least 5 minutes. Iyuzeh’s label describes this finding for the preserved reference product, not a demonstrated Iyuzeh-specific precipitation study. Do not mix solutions.

Adequate controlled pregnancy data are lacking. IV animal studies found developmental toxicity; they do not directly measure risk from prescribed human eye drops. Human milk excretion is unknown in these labels. Weigh maternal need, breastfeeding benefits and potential infant effects with the clinician.

U.S. pediatric safety/effectiveness are not established for either reviewed product. The labels report no overall safety/effectiveness differences between older and younger adult patients; this does not remove ocular comorbidity or handling considerations.

The reviewed labels give no renal- or hepatic-impairment adjustment schedule. Active latanoprost acid is metabolized mainly by the liver and metabolites are largely eliminated in urine; this pharmacology is not proof of a studied impairment-specific dose. Continue product dosing only within the individualized clinical plan.

Latanoprost primarily increases uveoscleral aqueous outflow. Pressure reduction begins about 3–4 hours after dosing, reaches maximum around 8–12 hours and persists at least 24 hours.

Corneal esterases convert the isopropyl-ester prodrug to active latanoprost acid. Aqueous-humor concentration peaks about 2 hours after instillation. Systemic active acid is cleared rapidly, with an approximately 17-minute plasma half-life; hepatic fatty-acid oxidation generates metabolites mainly excreted through the kidneys.

0.005% corresponds to 50 mcg/mL, or 0.05 mg/mL. This is an ophthalmic concentration, not a dose to swallow or inject. Each drop contains approximately 1.5 mcg in these product descriptions.

Follow intraocular-pressure response as part of glaucoma care and reassess noticeable pigmentation regularly. New eye injury, infection, conjunctivitis, eyelid reactions or surgery should prompt clinician advice about continuing the product; new visual loss needs prompt assessment.

Use only in the eyes as prescribed, once each evening. Demonstrate clean drop technique, lens removal and 5-minute spacing. Explain possible permanent iris color change and usually reversible lid/lash changes. For Iyuzeh, discard the individual container immediately after dosing even when liquid remains.

Do not compensate for missed treatment with extra drops. If excess dosing or ingestion occurs, contact a clinician/poison service with the product and amount; treatment is symptom-directed. Label IV experimental exposure findings are not an approved injection route or home-treatment instruction.

Viatris Xalatan: 2.5 mL fill in a 5 mL multidose bottle, NDC 58151-419-35, clear colorless preserved solution. Théa Iyuzeh: 30 single-dose 0.2 mL containers, NDC 82584-003-30, five units per foil pouch; opalescent white to slightly yellow solution. These examples do not identify every generic.

Both are sterile 0.005% ophthalmic solutions (50 mcg/mL; 0.05 mg/mL). Xalatan contains benzalkonium chloride 0.02%. Iyuzeh contains no preservative and is supplied only in the reviewed single-dose units. Do not confuse either with fixed-combination eye products.

Xalatan: protect from light; refrigerate unopened at 2–8°C. After opening, store up to 25°C for 6 weeks. Its label permits shipment up to 40°C for no more than 8 days; this is not a routine home-storage allowance. Iyuzeh: keep at 15–25°C in its original pouch; after opening the pouch, mark the date and discard unused units after 30 days. Each opened single-dose container is discarded immediately after administration.